Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego. The presentations will include new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D mutant non-small cell lung cancer, which will be featured in a plenary session. The company will also present two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with first line metastatic pancreatic ductal adenocarcinoma (PDAC), including monotherapy data and daraxonrasib plus chemotherapy combination data, the latter of which will be featured
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution, Ascendis, Arrowhead among RBC's top M&A candidates in biotech [Seeking Alpha]Seeking Alpha
- Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (RVMD) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- This One Data Readout Could Make Or Break Revolution Medicines [Seeking Alpha]Seeking Alpha
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- RVMD's page on the SEC website